Gallic Acid Enhances the Efficacy of BCR::ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia through Inhibition of Mitochondrial Respiration and Modulation of Oncogenic Signaling Pathways
Wei Xiang(Friedrich-Alexander-Universität Erlangen-Nürnberg), Charles Chuah(SingHealth)
Cited by 1
Related Papers
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
|Blood|2013|391
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
|Cancer Cell|2014|366
Posttranslational modification and mutation of histidine 50 trigger alpha synuclein aggregation and toxicity
|Molecular Neurodegeneration|2015|45